{"name":"Sorrento Therapeutics","slug":"sorrento","ticker":"SRNE","exchange":"NASDAQ","domain":"sorrentotherapeutics.com","description":"Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, provides therapeutic solutions in the United States and internationally. It offers chimeric antigen receptor T-cell therapy, dimeric antigen receptor T-cell therapy, and antibody-drug conjugates, as well as Seprehvec, SOFUSA, RTX, and SEMDEXA. The company also develops antiviral therapies and vaccines, including Abivertinib, COVI-MSC, COVI-AMG, COVIDROPS, and COVI SHIELD; and diagnostic test solutions, such as COVISTIX, COVITRACK, and Virex. Its products are used for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases treatment. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.","hq":"San Diego, CA","founded":0,"employees":"949","ceo":"Henry Ji","sector":"Immuno-Oncology / Pain / Drug Delivery","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$275,640","metrics":{"revenue":64270000,"revenueGrowth":31.1,"grossMargin":-245,"rdSpend":11304000,"netIncome":-572843000,"cash":80635000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2019"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"ZTALMY (STI-1314) patent cliff ($100M at risk)","drug":"ZTALMY (STI-1314)","type":"patent_expiry","sentiment":"negative"},{"date":"2032-06-01","label":"STI-606 patent cliff ($50M at risk)","drug":"STI-606","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":9,"colorKey":"oncology","drugs":[{"name":"STI-1492","genericName":"STI-1492","slug":"sti-1492","indication":"Other","status":"phase_1"},{"name":"CAR2 Anti-CD38 A2 CAR-T Cells","genericName":"CAR2 Anti-CD38 A2 CAR-T Cells","slug":"car2-anti-cd38-a2-car-t-cells","indication":"Other","status":"phase_1"},{"name":"Gene-Modified Cell Therapy","genericName":"Gene-Modified Cell Therapy","slug":"gene-modified-cell-therapy","indication":"Other","status":"phase_2"},{"name":"IG-001","genericName":"IG-001","slug":"ig-001","indication":"Other","status":"phase_1"},{"name":"PSC-04","genericName":"PSC-04","slug":"psc-04","indication":"Other","status":"phase_1"},{"name":"STI-1386","genericName":"STI-1386","slug":"sti-1386","indication":"Other","status":"phase_1"},{"name":"STI-5656","genericName":"STI-5656","slug":"sti-5656","indication":"Other","status":"phase_2"},{"name":"STI-6129","genericName":"STI-6129","slug":"sti-6129","indication":"Other","status":"phase_1"},{"name":"Zilretta","genericName":"Zilretta","slug":"zilretta","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"STI-1492","genericName":"STI-1492","slug":"sti-1492","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"CAR2 Anti-CD38 A2 CAR-T Cells","genericName":"CAR2 Anti-CD38 A2 CAR-T Cells","slug":"car2-anti-cd38-a2-car-t-cells","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Gene-Modified Cell Therapy","genericName":"Gene-Modified Cell Therapy","slug":"gene-modified-cell-therapy","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"IG-001","genericName":"IG-001","slug":"ig-001","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"PSC-04","genericName":"PSC-04","slug":"psc-04","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"STI-1386","genericName":"STI-1386","slug":"sti-1386","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"STI-5656","genericName":"STI-5656","slug":"sti-5656","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"STI-6129","genericName":"STI-6129","slug":"sti-6129","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Zilretta","genericName":"Zilretta","slug":"zilretta","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Sorrento Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Sorrento Therapeutics reported its financial results for the fourth quarter and full year 2023, highlighting revenue growth and progress in its pipeline.","drugName":"","sentiment":"neutral"},{"date":"2023-12-14","type":"deal","headline":"Sorrento Therapeutics Announces Collaboration with Merck KGaA to Develop Novel Cancer Therapies","summary":"Sorrento Therapeutics entered into a collaboration with Merck KGaA to develop novel cancer therapies, expanding its pipeline and capabilities.","drugName":"","sentiment":"positive"},{"date":"2023-09-11","type":"regulatory","headline":"FDA Grants Orphan Drug Designation to STI-1314 for the Treatment of Acute Myeloid Leukemia","summary":"The FDA granted orphan drug designation to STI-1314 for the treatment of acute myeloid leukemia, a rare and aggressive form of blood cancer.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2023-11-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2023-11-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2023-10-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2023-10-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2023-09-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2023-09-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2023-08-28","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2023-08-21","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2023-08-14","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2023-08-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2023-08-01","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2023-07-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxQaTRkR0tnSUgzUmJpaU5hWGsxOGFEMUNpVF9sOEhmTktNWkpGSEhLeTN5cWVIUTVIMVRCV1JDQjBVVU9Xb21HamR3UnNXT3ZodVJtT0toM3lYcTBFRERTbFZ4eEpSQ0dFZVZqTWNjT0VIZFNyeFVjOTlqelJlQzJmclhzR0w1aEI0VTZxMlJ6d0Rvd255NDVLZExoYXdhWHBlWTd1N2l3REVJUEVUTF9fdTBxM1RrMHdJQkVaRlNiU1RNYVl4ZGN1RF9CcFpDcXVyTmZqeWdXMnRpdDZ1ZVoxSUNGcw?oc=5","date":"2023-02-13","type":"pipeline","source":"proactiveinvestors.com","summary":"Sorrento Therapeutics stock plummets more than 60% on news of bankruptcy filing - proactiveinvestors.com","headline":"Sorrento Therapeutics stock plummets more than 60% on news of bankruptcy filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNd3pPeEsxRGlvMzRvRm14QjVGQm0xWFgyZUtvUC1zcTNIeUhlMjJTcHVhZzA0X0w2c01JUV9YZHJsU3puVUZkQ0YzdXplMGdWUEk2MGQ1aVJkWS1vQngxcFJ4ZExXenFuNXdFa3FmNUo4LVJFbGF5YUxNeG9iajJhN3dySE41c3M5Z3lPcTlSVzZzdUpwaThz?oc=5","date":"2023-02-13","type":"pipeline","source":"The Motley Fool","summary":"Why Sorrento Therapeutics Stock Is Crashing Today - The Motley Fool","headline":"Why Sorrento Therapeutics Stock Is Crashing Today","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQcFJqSXBaS0xQUzRCcFpJRzc4UjRfU3dVeVJ3bEZhUXM0aU1SUXgxaUJnMUZieE5IUl9UOXNiNWlJOGFDMlJGYVFRMGlZVHBJOFpQYVFxODVjQTk2dlpXVUZxLWhsTUpoTndoeTN2aUliZW16SW9QVklnTUxQRmRielJmaUxZTDZTbFpCU3d0cThDUQ?oc=5","date":"2023-02-13","type":"pipeline","source":"InvestorPlace","summary":"Why Is Sorrento Therapeutics (SRNE) Stock Down 40% Today? - InvestorPlace","headline":"Why Is Sorrento Therapeutics (SRNE) Stock Down 40% Today?","sentiment":"neutral"}],"patents":[{"drugName":"ZTALMY (STI-1314)","drugSlug":"sti-1314","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":100000000},{"drugName":"STI-606","drugSlug":"sti-606","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":50000000}],"drugCount":9,"phaseCounts":{"phase_1":6,"phase_2":2,"marketed":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol Myers Squibb","Merck & Co.","Janssen Pharmaceuticals"],"therapeuticFocus":["Immuno-Oncology","Pain","Drug Delivery"],"financials":{"source":"sec_edgar+yahoo","revenue":31432000,"revenuePeriod":"2019-12-31","revenueHistory":[{"value":31432000,"period":"2019-12-31"},{"value":13034000,"period":"2019-12-31"},{"value":5778000,"period":"2019-09-30"},{"value":6477000,"period":"2019-06-30"},{"value":6143000,"period":"2019-03-31"}],"grossProfit":29387000,"grossProfitHistory":[{"period":"2022-12-31","value":29387000},{"period":"2021-12-31","value":39873000}],"rdSpend":11304000,"rdSpendHistory":[{"period":"2022-12-31","value":221226000},{"period":"2021-12-31","value":206922000}],"sgaSpend":182337000,"operatingIncome":-378501000,"operatingIncomeHistory":[{"period":"2022-12-31","value":-378501000},{"period":"2021-12-31","value":-368045000}],"netIncome":-572843000,"netIncomeHistory":[{"period":"2022-12-31","value":-572843000},{"period":"2021-12-31","value":-428325000}],"eps":-1.37,"epsHistory":[{"period":"2022-12-31","value":-1.37},{"period":"2021-12-31","value":-1.45}],"cash":23634000,"cashHistory":[{"period":"2022-12-31","value":23634000},{"period":"2021-12-31","value":36665000}],"totalAssets":472840000,"totalLiabilities":494509000,"totalDebt":134504000,"equity":-18605000,"operatingCashflow":-293857000,"operatingCashflowHistory":[{"period":"2022-12-31","value":-293857000},{"period":"2021-12-31","value":-281821000}],"capex":-13657000,"capexHistory":[{"period":"2022-12-31","value":-13657000},{"period":"2021-12-31","value":-8871000}],"freeCashflow":-307514000,"dividendsPaid":null,"buybacks":0,"employees":949,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":0,"previousClose":0,"fiftyTwoWeekHigh":0.1,"fiftyTwoWeekLow":0,"fiftyTwoWeekRange":"2.0E-4 - 0.0985","fiftyDayAverage":0,"twoHundredDayAverage":0,"beta":0.31,"enterpriseValue":134393856,"forwardPE":0,"priceToBook":0,"priceToSales":0,"enterpriseToRevenue":2.09,"enterpriseToEbitda":-0.39,"pegRatio":0,"ebitda":-341593984,"ebitdaMargin":0,"freeCashflow":-57529500,"operatingCashflow":-234627008,"totalDebt":207600000,"debtToEquity":0,"currentRatio":0.41,"returnOnAssets":-40.8,"returnOnEquity":0,"analystRating":"","recommendationKey":"none","numberOfAnalysts":0,"targetMeanPrice":0,"targetHighPrice":0,"targetLowPrice":0,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0,"institutionHeldPercent":0.1,"sharesOutstanding":551281154,"floatShares":539113160,"sharesShort":64564656,"shortRatio":4.96,"shortPercentOfFloat":11.8,"epsTrailing":-0.09,"epsForward":0,"revenuePerShare":0.13,"bookValue":-0.38,"officers":[{"age":61,"name":"Dr. Henry H. Ji Ph.D.","title":"Chairman, President & CEO"},{"age":null,"name":"Dr. Scott  Schaus Ph.D.","title":"Chief Technology Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.sorrentotherapeutics.com","phone":"858 203 4100"}}